Tiziana Life Sciences plc ("Tiziana" or the "Company") Results of Annual General Meeting London, New York, 16 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK bio

of Annual General Meeting

York, 16 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"),

a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease

in oncology and immunology, today announces that at

the Annual General Meeting of the Company held at 10.00 a.m. on 16 July 2020, all of the resolutions were duly passed.

results of the proxy voting will be available shortly on the Company's website, www.tizianalifesciences.com.

person who arranged for the release of this announcement was Keeren Shah, Group Financial Controller.

Tiziana Life Sciences

Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human

disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab

is the only fully human anti-CD3 monoclonal antibody known to the company in clinical development in the world. This compound

has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH),

primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD),

psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

information contained in this announcement is inside information for the purposes of article 7 of regulation 596/2014